| 2.01 -0.01 (-0.5%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.42 |
1-year : | 2.62 |
| Resists | First : | 2.07 |
Second : | 2.25 |
| Pivot price | 2.01 | |||
| Supports | First : | 1.79 | Second : | 1.49 |
| MAs | MA(5) : | 2 |
MA(20) : | 2.01  |
| MA(100) : | 2.18 |
MA(250) : | 2.61 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 65.3 |
D(3) : | 61.2 |
| RSI | RSI(14): 44.3 |
|||
| 52-week | High : | 4.62 | Low : | 1.77 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CHEK ] has closed above bottom band by 46.2%. Bollinger Bands are 70.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.05 - 2.06 | 2.06 - 2.07 |
| Low: | 1.96 - 1.98 | 1.98 - 1.99 |
| Close: | 1.99 - 2.01 | 2.01 - 2.03 |
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. The company was incorporated in 2004 and is based in Isfiya, Israel.
Sat, 20 Jul 2024
Check-Cap (NASDAQ:CHEK) Now Covered by Analysts at StockNews.com - Defense World
Thu, 28 Mar 2024
Check-Cap Ltd. Announces Merger with Nobul AI - TipRanks
Tue, 26 Mar 2024
Why Is Check-Cap Stock Trading On Tuesday? - Check-Cap (NASDAQ:CHEK) - Benzinga
Tue, 26 Mar 2024
Check-Cap jumps on Nobul AI business combination (NASDAQ:CHEK) - Seeking Alpha
Mon, 25 Mar 2024
Nobul and Check-Cap announce definitive merger agreement - Investing.com
Wed, 20 Mar 2024
Check-Cap Ltd. Appoints New Interim CEO - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 6 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 25 (%) |
| Held by Institutions | 0.1 (%) |
| Shares Short | 133 (K) |
| Shares Short P.Month | 191 (K) |
| EPS | -3 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.05 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -31.7 % |
| Return on Equity (ttm) | -54.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.02 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -17 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -0.68 |
| PEG Ratio | 0 |
| Price to Book value | 0.49 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.7 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|